Furthermore, the overall population of enzalutamide-treated tumor cells expressing NAIP significantly decreased by 1.5-fold (P < 0.01) compared to untreated tumors, and there was a significant 2.2-fold increase (P < 0.01) in tumor area that did not express NAIP in enzalutamide-treated tumors compared to untreated tumors. The gene discussed is NAIP; the disease is neoplasm.